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ABSTRACT
Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths 
in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The 
prevalence of T2DM is increasing due to obesity. Clinical guidelines recommend the 
use of metformin as the first-line treatment, followed by the addition of 1 or 2 oral 
antidiabetic drugs (OADs), such as sulphonylurea (SU), an alpha-glucosidase inhibitor, or 
thiazolidinediones (TZDs). Recently, newer agents such as dipeptidyl peptidase 4 (DPP-4) 
inhibitors have been added to those treatment algorithms. The DPP-4 inhibitor is a class 
of OAD that inhibits the DPP-4 enzyme. Sitagliptin, saxagliptin, vildagliptin and linagliptin 
are DPP-4 inhibitors available for the treatment of T2DM in Indonesia and many other 
countries. The DPP-4 inhibitors have similar glycemic efficacy. However, they produce 
a moderate improvement in glycated hemoglobin (A1C). There are limited numbers of 
head-to-head trials of DPP-4 inhibitors. In addition, there are no data on the long-term 
DPP-4 inhibitors use safety (more than two years), mortality, diabetic complications, or 
health-related quality of life. Although DPP-inhibitors are not used as initial treatment 
for a majority of patients with T2DM, DPP-4 inhibitors can be used as add-on therapy 
in T2DM patients who are intolerant to, have contraindications for, or uncontrolled with 
the use of metformin, SU, or TZDs. The exact role of DPP-4 inhibitors among several 
other agents to manage T2DM is not clear. There are only a small number of long-term 
studies on DPP-4 inhibitors assessing the glycemic decrease efficacy, important clinical 
outcomes (cardiovascular events, mortality), or safety. In patients with chronic renal 
failure considered to use DPP-4 inhibitors, linagliptin can be recommended. There are 
inadequate data to assess the effect of DPP-4 inhibitors on the occurrence of acute 
pancreatitis. Overall, DPP-4 inhibitors are well-tolerated.
ABSTRAK
Diabetes melitus (DM) merupakan penyakit kronis yang menyebabkan sekitar 1,5 juta 
kematian pada tahun 2012. Prevalensi DM tipe 2 (DMT2) menapai 90% dari keseluruhan 
DM di seluruh dunia. Prevalensi DMT2 ini meningkat karena faktor obesitas. Pedoman 
pengobatan merekomendasikan penggunaan metformin sebagai obat lini pertama, bisa 
diikuti dengan penambahan 1 atau 2 oral antidiabetes oral (OAD), seperti sulfonilurea 
(SU), inhibitor alpha-glucosidase, atau thiazolidinediones (TZD). Obat baru golongan 
penghambat dipeptidil peptidase-4 (DPP-4) telah ditambahkan ke algoritma pengobatan 
DM. Penghambat DPP-4 inhibitor adalah golongan OAD yang bekerja menghambat enzim 
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DPP-4. Sitagliptin, saxagliptin, vildagliptin dan linagliptin termasuk golongan penghambat 
DPP-4 yang beredar di Indonesia dan beberapa negara lain. Penghambat DPP-4 memiliki 
efek hipoglikemik yang setara OAD lain, namun obat ini dapat meningkatan hemoglobin 
terglikasi (A1C) secara moderat. Uji klinik penghambat DPP-4 sebagai antidiabetes 
jumlahnya terbatas. Selain itu tidak ada data tentang keamanan penggunaan obat 
ini dalam jangka panjang (lebih dari dua tahun), kematian, komplikasi diabetes, atau 
kualitas-hidup pasien. Meskipun penghambat DPP-4 tidak digunakan sebagai terapi awal 
untuk pasien DMT2, obat ini dapat digunakan sebagai terapi tambahan pada pasien yang 
tidak toleran, ada kontraindikasi, atau tidak terkontrol pada penggunaan metformin, SU, 
atau TZD. Peran sebenarnya dari penghambat DPP-4 di antara obat antidiabetes lainnya 
dalam pengelolaan DMT2 belum begitu jelas. Belum banyak penelitian jangka panjang 
untuk mengkaji efek hipoglikemik, luaran klinik penting seperti efek samping terhadap 
kardiovaskular dan kematian yang ditimbulkan, atau keamanan dari penghambat DPP-4. 
Pada pasien gagal ginjal kronis dapat menggunakan penghambat DPP-4 linagliptin  sebagai 
obat pilihan. Data untuk mengkaji efek penggunaan penghambat DPP-4 terhadap kejadian 
pankreatitis akut tidak cukup tersedia. Secara keseluruhan, penggunaan penghambat 
DPP-4 dapat ditoleransi oleh pasien.
Keywords : type 2 diabetes mellitus - dipeptidyl peptidase 4 (DPP-4) inhibitors - sitagliptin, 
saxagliptin - vildagliptin - linagliptin
INTRODUCTION
Diabetes mellitus (DM) is a chronic 
disease which caused around 1.5 million 
deaths in 2012 according to the World Health 
Organization. It is estimated that DM will be 
the seventh leading cause of mortality in 2030. 
Type 2 diabetes mellitus (T2DM) accounts 
for 90% of DM worldwide. The prevalence 
of T2DM is increasing due to obesity.1 The 
goals in management of T2DM are directed to 
eliminate symptoms and to prevent or reduce 
the progress to micro- and macrovascular 
complications. The management includes 
diet, exercise, medications and blood glucose 
and T2DM complications monitoring. A wide 
range of oral anti-diabetic drugs (OADs) is 
effective in decreasing blood glucose level. 
however, they are also associated with side 
effects that may have an impact on healthcare 
resource use and quality of life.2 
Clinical guidelines recommend the use 
of metformin as the first-line treatment unless 
contraindicated, followed by the addition of 1 
or 2 OADs, such as sulphonylurea (SU), alpha-
glucosidase inhibitor, or thiazolidinediones 
(TZDs).2 Recently, newer agents such as 
dipeptidyl-peptidase 4 (DPP-4) inhibitors have 
been added to those treatment algorithms. The 
approach is to use OADs with complementary 
mechanisms of action in combination. 
Pharmacological treatment for type 2 diabetes 
is aimed to increase insulin availability, to rise 
the sensitivity to insulin, to prolong insulin 
absorption from gastrointestinal tract, or to 
rise glucose excretion via urine. Treatment 
with DPP-4 inhibitors affect the glycemic 
control through several mechanisms i.e. 
by increasing glucose-dependent insulin 
secretion, delaying gastric emptying, and 
decreasing postprandial glucose and food 
intake. Dipeptidyl peptidase-4  inhibitor 
usually does not cause hypoglycemia, except 
when it is combined with a treatment that may 
lead to hypoglycemia.3,4
Dipeptidyl peptidase-4 inhibitor is a 
class of oral antidiabetic drug that inhibits 
the DPP-4 enzyme. Dipeptidyl peptidase-4 
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is an enzyme expressed on the surface of 
most cell types that inactivates various other 
bioactive peptides. Therefore, the inhibition 
potentially affects glucose regulation through 
several mechanisms. Sitagliptin, saxagliptin, 
vildagliptin and linagliptin are DPP-4 
inhibitors available for the treatment for 
T2DM in Indonesia and many other countries. 
Vildagliptin is available in several countries, 
but not in the United State of America. If a 
DPP-4 inhibitor will be used on patients with 
chronic renal disease (estimated glomerular 
filtration rate [eGFR] < 30 mL/min), 
linagliptin is the treatment of choice because 
its elimination is mainly through enterohepatic 
system.3-6
DISCUSSION
Efficacy of DPP-4 inhibitors.
Dipeptidyl peptidase-4 inhibitors have 
similar glycemic efficacy. They produce 
a moderate improvement in glycated 
hemoglobin (A1C). However, there are limited 
numbers of head-to-head trials, and there are 
no data on the use of long-term use (more 
than two years) safety, mortality, diabetic 
complications, or health-related quality of 
life. In a 18-week study of saxagliptin (5 mg) 
versus sitagliptin (100 mg) in 800 patients who 
were uncontrolled with stable dose metformin, 
there was a similar reduction of A1C values 
(-0.52% vs -0.62%).4 Furthermore, the results 
from meta-analysis of the studies comparing 
sitagliptin and placebo or vildagliptin and 
placebo showed similar efficacy (mean 
difference of A1C values -0.74% and -0.73%, 
95%CI -0.84 vs -0.63 and -0.94 vs -0.52, 
respectively, for sitagliptin and vildagliptin 
compared to placebo).5 Other meta-analysis 
on sitagliptin and vildagliptin also reported 
similar findings.6 Although DPP-inhibitors are 
not used as initial treatment for a majority of 
patients with T2DM, DPP-4 inhibitors can be 
used as add-on therapy in T2DM patients who 
are intolerant to, have contraindications for, or 
uncontrolled with the use of metformin, SU or 
TZDs. 
Safety of DPP-4 inhibitors 
Cardovascular effect
There are increasing numbers of trials 
evaluating the cardiovascular effects of DPP-4 
inhibitors. Although the data showed that there 
was no increase in the risk of cardiovascular 
adverse effects with short-term use of DPP-
4 inhibitors combined with other oral agents, 
long-term clinical trials are needed to assess 
the cardiovascular safety of DPP-4 inhibitors 
use. Until recently, there have been no 
studies confirming the initial statement on the 
beneficial effect of DPP-4 inhibitors on the 
risk of cardiovascular diseases.
Use in chronic renal failure
Sitagliptin, saxagliptin, and vildagliptin 
need a dosage adjustment in patients with 
chronic renal failure. Linagliptin is mainly 
eliminated through enterohepatic system, 
therefore it does not need any dosage 
adjustment. 
Pharmcaology of DPP-4 inhibitors 
Sitagliptin
Sitagliptin (FIGURE 1) is a DPP-4 
inhibitor that is approved as a treatment for 
T2DM (as second-line drug for those who 
are non-responders to single therapy, such 
as SU, metformin, or TZDs, and as a third-
line drug when dual therapy with metformin 
and a SU does not give an adequate glycemic 
control. Usual dose of sitagliptin is 100 
mg once daily, with a reduction to 50 mg 
for patients with moderate-severe renal 
insufficiency (glomerular filtration rate [GFR] 
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30-50 mL/min) and to 25 mg for patients with 
severe renal insufficiency (< 30 mL/min).7 
Sitagliptin is also effective as a combination 
with metformin,8-10 a TZD,11 or a SU,12 and 
one study reported that sitagliptin has a 
similar ability to glipizidein reducing the A1C 
value.10 The recommended dose of sitagliptin 
is 100 mg once daily. Sitagliptin can be taken 
with or without food. Sitagliptin-metformin 
is available as a single tablet (50mg/500mg, 
50mg/850mg, 50mg/1000mg sitagliptin and 
metformin respectively) to be taken twice 
daily along with food.13
FIGURE 1. Chemical structure of sitagliptin
Saxagliptin
Saxagliptin (FIGURE 2) is approved as 
initial pharmacological treatment for T2DM 
or as a second-line agent in those who are 
non-responders to single agent, such as a SU, 
metformin, or a TZD. Usual dose of saxagliptin 
is 2.5 or 5 mg once daily, with the 2.5 mg dose 
is recommended for patients with moderate-
severe chronic renal failure (glomerular 
filtration rate [GFR] ≤ 50 mL/min) and for 
patients who are using cytochrome P450 
3A4/5 strong inhibitors (e.g., ketoconazole).14 
Saxagliptin as monotherapy decreases the 
A1C.15,16 As an example, in a 24-weeks 
randomized trial, saxagliptin (2.5, 5, or 10 
mg daily) versus placebo in 401 patients with 
T2DM without therapy and with average 
baseline A1C value of 7.9%, saxagliptin 
reduced 0.4%, 0.5%, and 0.5% A1C values, 
respectively for each dose, compared with 
0.2% increase in placebo group.16
FIGURE 2. Chemical structure of saxagliptin
Saxagliptin is also effective when it is 
combined with metformin,17,18 a SU,19 or a 
TZD.14 As an example, in a 24-weeks trial 
in 743 patients who were uncontrolled with 
metformin monotherapy (1500-2500 mg/
day), add-on saxagliptin (2.5-5 mg once daily) 
versus placebo improved the A1C values 
(-0.6% and -0.7%vs +0.1% from the baseline 
value).17 The recommended dosage of 
saxagliptin is 2.5 mg or 5 mg once daily taken 
regardless of meals. Saxagliptin tablets must 
not be split or cut. Saxagliptin-metformin is 
available in a combination tablet (5 mg/500 
mg, slow-release saxagliptin and metformin 
combination) to be taken once daily.
Vildagliptin
Vildagliptin is another dipeptidyl 
peptidase-4 (DPP-4) inhibitor available 
in several countries, even though it is not 
approved by the Food and Drug Administration 
(FDA) yet. Generally the dose is 50 mg twice 
daily if it is used as a monotherapy, with a 
metformin, or with a thiazolidinedione, and 50 
mg daily (in the morning) if it is used with a 
sulphonylurea.20 There is no need to adjust the 
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dose in patients with mild renal dysfunction 
(creatinine ≥ 50 mL/min). In patients with 
moderate or severe renal dysfunction, the 
dose is 50 mg once daily. Vildagliptin is 
effective in a combination with metformin.21,22 
a thiazolidinedione,23 or insulin.24
FIGURE 3. Chemical structure of vildagliptin
In a study on patients who were naïve 
to treatment, vildagliptin decreased the A1C 
values similarly to rosiglitazone, but less 
effective than metformin.25,26 As an example, 
in a 52-weeks non-inferiority trial on 
vildagliptin (100 mg daily) versus metformin 
(titrated to 2000 mg daily) in 780 patients with 
type 2 diabetes who were naïve to treatment, 
metformin was better (vildagliptin was not 
non-inferior) in reducing the A1C values (the 
difference between groups was 0.4%, 95%CI 
0.28-0.65).26 Target A1C (< 7.0%) was reached 
by 45% and 35% patients who received 
metformin and vildagliptin, respectively. 
When used in combination with metformin, 
in combination with TZD, in combination 
with metformin and a SU, or in combination 
with insulin (with or without metformin), the 
recommended daily dose of vildagliptin is 
100 mg, administered as one dose of 50 mg 
in the morning and one dose of 50 mg in the 
evening. When used in dual combination with 
a SU, the recommended dose of vildagliptin is 
50 mg once daily administered in the morning. 
In this patient population, vildagliptin 
100 mg daily was no more effective than 
vildagliptin 50 mg once daily. When used in 
combination with a SU, a lower dose of the 
SU may be considered to reduce the risk of 
hypoglycaemia. Doses higher than 100 mg are 
not recommended. Vildagliptin-metformin is 
available in a combination tablet (50 mg/500 
mg, 50 mg/850 mg, 50 mg/1000 mg of 
vildagliptin and metformin)
Linagliptin
Linagliptin (FIGURE 4) is available 
to be used as an add-on therapy to diet and 
exercise in adults with type 2 diabetes. Usual 
dose of linagliptin is 5 mg once daily, with or 
without food. Linagliptin is mainly eliminated 
through enterohepatic system. No dosage 
adjustment is needed in patients with renal 
or liver dysfunction. Reagents of CYP3A4 or 
P-glycoprotein (e.g., rifampin) may decrease 
the effectivity of linagliptin. Therefore, 
patients who need these drugs should receive 
an alternative to linagliptin.
FIGURE 4. Chemical structure of linaglip
Efficacy of linagliptin in combination 
with metformin,27,28 glimepiride,29 metformin 
and SU combination,30 or pioglitazone31 
is illustrated by the following trials: there 
were several head-to-head trials comparing 
linagliptin and other agents. In a 2-years 
non-inferiority trial on glimepiride (1-4 mg, 
average dose of 3 mg) versus linagliptin (5 
mg), both were given once daily, in 1551 
patients with type 2diabetes who were 
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inadequately controlled with metformin 
(average baseline value of A1C 7.7%), a 
significantly better change in A1C values was 
shown in glimepiride (-0.36%vs -0.16%), 
although linagliptin was statistically non-
inferior to glimepiride.32 The decrease in 
A1C values for both drugs in this long-term 
study was small. This might be related to 
the adjustment to baseline factors (baseline 
A1C values, group of therapy, and previous 
antidiabetic drugs) or high drop-out rate 
(~40%), and missing data estimation with the 
last-observation-carried-forward method. The 
increased dose in glimepiride was associated 
with a higher risk of hypoglycemia (36% vs 
7% patients) and an increase in body weight 
(+1.3 vs -1.4 kg with linagliptin). There was 
too small number of cardiovascular events 
to take any significant conclusion. The 
recommended dose of linagliptin is 5 mg once 
daily. Linagliptin tablets can be taken with 
or without food. Linagliptin-metformin is 
available in a combination tablet (2.5 mg/500 
mg, 2.5 mg/850 mg, 2.5 mg/1000 mg of 
linagliptin and metformin) taken twice daily 
with food.
Adverse effects 
Dipeptidyl peptidase-4 inhibitors are well 
tolerated in short-term studies. There were no 
effects on body weight or hypoglycemic risk 
(with no concomitant treatment with insulin 
or SU). Commonly reported adverse effects 
are headache, nasopharyngitis, and upper 
respiratory tract infection.33,34 Several, but not 
all,8,22 studies have reported a small increase 
in the risk of gastrointestinal adverse effects 
with sitagliptin. Long-term safety with DPP-4 
inhibitors has not been determined.
Immunological function
Although DPP-inhibitors are relatively 
specific for glucagon-like peptide 1 (GLP-1), 
long-term consequence of DPP-4 inhibition 
and its impact on the other DPP-4 substrates 
are not known. Because of the characteristics 
of dipeptidyl peptidase substrates and 
specialized variable DPP-4 inhibitors, each 
agent in this class is needed to be studied 
individually for drug adverse effects.35 
There is a possibility that the risk of adverse 
effect is higher in the less-selective DPP-
inhibitors. Residual cross-over with other 
substrates of DPP-4, particularly related to the 
immunological function, is still of interest, 
although it has not been reported yet in the 
short-term clinical trials. In three head-to-
head trials, there were no significant clinical 
differences in adverse effects between DPP-
inhibitors. There are very few data available 
to develop a conclusion on cardiovascular 
effects or mortality.
Pancreas
Acute pancreatitis case reported on the 
use of DPP-4 inhibitors. Nowadays there 
are inadequate data to establish the causal-
effect relationship. Pancreatitis should be 
considered in patients with persistently severe 
gastric pain (with or without nausea), and 
DPP-4 inhibitors should be stopped in these 
patients. If pancreatitis is confirmed, DPP-
4 inhibitors are not to be restarted. DPP-4 
inhibitors should also not be used in patients 
with a history of pancreatitis.
There are several postmarketing reports 
on acute pancreatitis cases in the users of 
sitagliptin, saxagliptin, and alogliptin.36-38 
This finding is similar with the case reports 
on pancreatitis in the users of GLP-1 receptor 
agonists. In a retrospective cohort study 
on a claim database, the incidence of acute 
pancreatitis was 5.6 cases per 1000 patient-
years, which is similar to the incidence in 
diabetes control group.39 However, in a 
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population-based case-control study using 
insurance database, the treatment with GLP-
1 (sitagliptin and exenatide) was associated 
with an increased risk in hospitalization due 
to acute pancreatitis (adjusted odds ratio [OR] 
2.07, 95%CI 1.36-3.13).40 In contrast, a meta-
analysis of several randomized trials did not 
find any increased risk of acute pancreatitis.41,42 
Overall incidence of pancreatitis was low (35 
cases out of 68,318 patients, 20 in the users of 
DPP-4 inhibitors and 15 in the control group).42 
In a population-based cohort study, there 
were no differences in the risk of pancreatitis 
occurrence in patients who received GLP-
1 treatment or sulphonylurea (1.45 and 1.47 
per 1000 patient-years, respectively).43 More 
carefully planned observational studies are 
needed to assess the true risk.
There was a report on the increased 
risk of subclinical pancreatic inflammation, 
pancreatic cancer, and neuro endocrine tumor 
in the users of sitagliptin.36,44-46 Causal-effect 
relationship could not be determined. After 
reviewing the available data, the FDA and 
the European Medicines Agency agreed that 
there was no adequate evidence to confirm the 
increased risk inpancreatic cancer in the users 
of GLP-1 receptor agonists.47-49 However, 
because the risk has not been eliminated yet, 
monitoring and reporting of adverse effects 
are still continued.47,49,50
Liver function
Although it is rare, liver dysfunction 
cases (the increase in liver enzymes, hepatitis) 
have been reported in patients who used 
vildagliptin.34,51 Consequently, liver function 
test results should be evaluated before starting 
vildagliptin, and at 3-months intervals during 
the first year of treatment.51 If there is an 
increase in aspartate aminotransferase (AST) 
or alanine aminotransferase (ALT) equals to 
or more than three times the upper normal 
value, the drug should be stopped.
Skin
Several DPP-4 inhibitors, including 
vildagliptin and saxagliptin, have been 
associated with serious skin reactions 
during preclinical studies on animals (red 
discoloration and swelling, blistering and skin 
sloughing with necrosis with higher doses).52,53 
Skin lesions also occurred in normal volunteers 
given 4-6 times suggested treatment dose 
of vildagliptin.54 In postmarketing reports, 
sitagliptin, saxagliptin, and linagliptin 
have been associated with hypersensitivity 
reactions, including anaphylaxis, angioedema, 
and blistering skin conditions, including 
Stevens-Johnson syndrome.55 DPP-4 
inhibitors are contraindicated in patients with 
a history of hypersensitivity reaction in the 
previous exposure.56
CONCLUSION
Dipeptidyl peptidase-4 (DPP-4) inhibitor 
is a class of oral antidiabetic drug which 
inhibits the DPP-4 enzyme. It can be used 
as add-on therapy in patients who have 
inadequate control with metformin, TZD, 
or SU. Dipeptidyl peptidase-4 inhibitors are 
not considered as initial therapy for most 
patients with T2DM. The exact role of DPP-
4 inhibitors among several other agents 
to manage T2DM is not clear. There were 
only a small number of long-term studies 
on DPP-4 inhibitors assessing the glycemic 
decrease efficacy, important clinical outcomes 
(cardiovascular events, mortality), or safety. In 
patients with chronic renal failure (estimated 
glomerular filtration rate [eGFR] < 30 mL/
min) considered to use DPP-4 inhibitors, 
linagliptin can be chosen. There are inadequate 
data to assess the effect of DPP-4 inhibitors on 
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the occurrence of acute pancreatitis. Overall, 
DPP-4 inhibitors are well-tolerated.
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